Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Status:
Completed
Trial end date:
2016-03-28
Target enrollment:
Participant gender:
Summary
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in
patients with visual impairment due to macular edema secondary to BRVO